Abraxis BioScience

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

Retrieved on: 
Wednesday, November 30, 2022
Marketing, COVID-19, Exchange, PLE, Parke-Davis, Sarcoma, Peptide, University, Acceleration, TG, Risk, Novartis, PDC, Therapy, Employment, Safety, Sanofi, Patient, Follicular lymphoma, ImClone Systems, Regulation, Common stock, Neuroblastoma, Drug discovery, Hematology, Security (finance), Lymphoma, News, Cancer, Business administration, Bachelor of Business Administration, Research, Abraxis BioScience, Christian democracy, Brain, FDA, WM, Pharmaceutical industry, Management, Lenalidomide

FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022.
  • Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology.
  • As we prepare for the approval of iopofosine, his professional background is ideally suited for our newly created position of chief commercial officer and we look forward to his leadership, said James Caruso, president and chief executive officer of Cellectar.
  • Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.

Ziosoft Introduces Next Generation Ziostation Platform at Annual Radiological Society of North America Conference

Retrieved on: 
Monday, November 28, 2022
Marketing, Software, AI, The San Diego Union-Tribune, Weeping Angel, ImmunityBio, RSNA, Workflow, 3D, MD, Rembrandt, Google Images, Automation, Revora, Abraxis BioScience, Video game console, Video game, NantWorks

CHICAGO, Nov. 28, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer in 3D/4D AI medical visualization, is introducing its newest software for its flagship Ziostation system at the annual Radiologicaly Society of North America (RSNA) being held November 27-30, 2022 in Chicago. The Revoras platform (work in progress) offers numerous productivity enhancements and new visualization technology including the unique Ziosoft Rembrandt image rendering capability.

Key Points: 
  • The Revoras platform (work in progress) offers numerous productivity enhancements and new visualization technology including the unique Ziosoft Rembrandt image rendering capability.
  • It is enabled, along with other enhancements, through our new, advanced Revoras platform, which is being introduced at RSNA this year."
  • Advanced imaging technology immerses users in simulated environments for exploration, analysis, synthesis and presentation, all of which are enabled by the Revoras platform.
  • "Revoras is a comprehensive advanced imaging platform that is the newest generation Ziosoft technology," said Rajeev Taitriya, vice president of marketing and business development for Ziosoft.

Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 22, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Genentech, RCC, Conference, TNBC, Cancer, Abraxis BioScience, Piper Sandler Companies, Bristol Myers Squibb, Patient, Pharmaceutical industry, Kerosene, Infinity

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (Infinity or the Company), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 December 1, 2022 in New York.

Key Points: 
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (Infinity or the Company), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 December 1, 2022 in New York.
  • A replay of the presentation will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the event.
  • Infinity Pharmaceuticals, Inc. (Infinity or the Company), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.
  • MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results

Retrieved on: 
Friday, November 18, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Australian Research Council, Engineering, Security (finance), ARC, Growth, Twist Bioscience, Risk, Boston, Investment, Agriculture, Administration, PIN, Synthetic biology, Factory, PEGS, DNA, Abraxis BioScience, Research, Doctor of Philosophy, Gorman Joint School District, Development, Biology, Martek Biosciences Corporation, Sutro Biopharma, Gene, Operating cost, United Kingdom, Silicon, Exome, Annual report, Drug discovery, Liquid biopsy, Genomics, Telephone, MRD, EBITDA, NGS, Video game, Tobacco, Spice, Reinsurance, Bookkeeping, Rope, Air cargo, Future, COVID-19, Illumina

Cost of Revenues: Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021.

Key Points: 
  • Cost of Revenues: Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021.
  • Research and Development Expenses: Research and development expenses for fiscal 2022 were $120.3 million compared to $69.1 million for fiscal 2021.
  • Orders: Total orders received for the fourth quarter of fiscal 2022 were $62.1 million compared to $45.2 million for the same period of fiscal 2021.
  • Revenue: Total revenues for the fourth quarter of fiscal 2022 were $57.3 million compared to $38.0 million for the same period of fiscal 2021.

Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Genentech, Event, Investment, Partnership, Patent, RCC, TNBC, Cancer, Annual report, Security (finance), Abraxis BioScience, Risk, Bristol Myers Squibb, COVID-19, Research, Webcast, Patient, Pharmaceutical industry, Kerosene, Infinity

Third Quarter 2022 Financial Results:

Key Points: 
  • Third Quarter 2022 Financial Results:
    At September 30, 2022, Infinity had total cash and cash equivalents of $47.2 million, compared to $80.7 million at December 31, 2021.
  • Research and development expenses for the third quarter of 2022 were $7.7 million, compared to $7.1 million in the same period in 2021.
  • Infinitys 2022 financial guidance remains as follows:
    Net Loss: Infinity continues to expect net loss for 2022 to range from $40 million to $50 million.
  • Infinity will host a conference call today, November 14, 2022, at 8:30 AM ET to discuss these financial results and business updates.

Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib

Retrieved on: 
Monday, November 14, 2022
Pharmaceutical, Health, Oncology, Clinical Trials, FDA, Genentech, Partnership, Patent, RCC, TNBC, Cancer, Annual report, Security (finance), Abraxis BioScience, Risk, Bristol Myers Squibb, Patient, Pharmaceutical industry, Kerosene, Infinity

MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.

Key Points: 
  • MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.
  • For more information on Infinity, please refer to Infinity's website at www.infi.com .
  • This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
  • Such forward-looking statements include the Companys guidance with respect to the therapeutic potential of eganelisib and the Company's ability to execute on its strategic plans.

Next-Generation Sequencing Services Market is anticipated to grow at 15.4% CAGR till 2028, Says Brandessence Market Research

Retrieved on: 
Thursday, November 10, 2022
Ion semiconductor sequencing, Laboratory, Oxford Nanopore Technologies, Investment, Informatics, Partnership, Immunotherapy, Research, Gene, Abraxis BioScience, Transcriptome, ABI Solid Sequencing, Oncology, Attention, Biomarker, Cancer, Clinical trial, Public health, Patient, Growth, Asia-Pacific, NGS, FDA, Medical imaging, Fine chemical, Illumina

Asia Pacific is a market which is going to grow at the fastest as a revenue earner in the coming years.

Key Points: 
  • Asia Pacific is a market which is going to grow at the fastest as a revenue earner in the coming years.
  • This is going to grow the market significantly in the coming years particularly in the post pandemic period in Asia.
  • But the manufacturers have been strategizing constantly in their research and development for addressing the challenges.
  • On Special Requirement Next-Generation Sequencing Services Market Report is also available for below region:

PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000

Retrieved on: 
Wednesday, October 26, 2022
U.S. Securities and Exchange Commission, Infection, Interest, Microbiology, Sequel, Investor relations, Deep learning, Child, Architecture, Population, DNA methylation, Google Health, Workflow, NVIDIA, Genomics, NASDAQ, ZMW attack, PARK, Cheung, Research, Corteva, Security (finance), Technology, Private Securities Litigation Reform Act, Apple IIe, Marketing, MD, Doctor of Philosophy, SMRT, Securities Exchange Act of 1934, Genetics, Genome, European, DNA, Pacific Biosciences, Solution, Computing, Algorithm, Antibiotics, Fine chemical, Medical imaging, High fidelity, Abraxis BioScience, Biotechnology

MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio's celebrated HiFi sequencing technology. Revio is designed to provide customers with the ability to sequence up to 1,300 human whole genomes per year at 30-fold coverage for less than $1,000 per genome. With this scale and pricing, PacBio believes Revio will enable the use of HiFi sequencing for large studies in human genetics, cancer research, agricultural genomics, and more.

Key Points: 
  • With this scale and pricing, PacBio believes Revio will enable the use of HiFi sequencing for large studies in human genetics, cancer research, agricultural genomics, and more.
  • Revio will further unleash that power by adding high throughput and affordability," said Christian Henry, President and Chief Executive Officer of PacBio.
  • Revio will run up to four SMRT Cells in parallel, which provides up to 100 million ZMWs for sequencing single molecules simultaneously.
  • Combined with significant advances in our compute, Revio will deliver shorter run times and a 15-fold increase in HiFi data.

PacBio Announces Onso, the Highly Accurate Short-Read Sequencing Platform

Retrieved on: 
Wednesday, October 26, 2022
U.S. Securities and Exchange Commission, Infection, Interest, High fidelity, Microbiology, Investor relations, Efficiency, Science, Workflow, Weill Cornell Medicine, NASDAQ, Gene editing, Research, Security (finance), Technology, Private Securities Litigation Reform Act, Harvard University, Marketing, Broad Institute, Ecosystem, Securities Exchange Act of 1934, MIT, Corteva, Genomics, Recurrence, SBB, Genome, Pacific Biosciences, DNA, Single-cell analysis, Solution, Book, Online shopping, Medical imaging, Fine chemical, Abraxis BioScience, Biotechnology

MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of external beta testing of the Onso™ sequencing system. This innovative benchtop short-read DNA sequencing platform is expected to provide an extraordinary level of accuracy by utilizing PacBio's unique sequencing by binding (SBB) technology.

Key Points: 
  • MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of external beta testing of the Onsosequencing system.
  • This innovative benchtop short-read DNA sequencing platform is expected to provide an extraordinary level of accuracy by utilizing PacBio's unique sequencing by binding (SBB) technology.
  • "We are excited to see how researchers will leverage the ground-breaking sequencing accuracy that we expect Onso to deliver.
  • "Onso is designed to deliver highly accurate sequencing reads, support scalable, flexible, and cost-optimized operation, and enable customers to feel more confident in their science.

PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15

Retrieved on: 
Wednesday, October 26, 2022
U.S. Securities and Exchange Commission, Infection, High fidelity, Microbiology, NASDAQ, Research, Security (finance), Technology, Private Securities Litigation Reform Act, Q&A, Securities Exchange Act of 1934, SBB, Pacific Biosciences, Internet, Solution, Risk, Broadcasting, Medical imaging, Abraxis BioScience

MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.

Key Points: 
  • PacBio will also host its Inaugural Investor Day on Tuesday, Nov. 15, 2022, at 8:00 a.m. Eastern Time.
  • The event will feature presentations by members of PacBio's executive team and include Q&A sessions.
  • Both events will be webcast live and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ .
  • We plan to provide additional information during our third quarter earnings call on Nov. 7, 2022.